Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Search Results to Anthony David Elias

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Elias, Anthony

Item TypeName
Academic Article A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer.
Academic Article Triple-negative breast cancer: a short review.
Academic Article Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue.
Academic Article Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Concept Receptor, ErbB-2
Academic Article Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR.
Academic Article Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.
Academic Article Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Academic Article 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Academic Article Adaptive Randomization of Neratinib in Early Breast Cancer.
Academic Article Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison.
Academic Article Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
Academic Article Triple-negative breast cancer in the elderly.
Academic Article Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Academic Article NCCN Guidelines Updates: Breast Cancer.
Academic Article MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Academic Article Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
Academic Article Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.
Academic Article Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Academic Article Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Academic Article Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Academic Article Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Search Criteria
  • Receptor
  • ErbB
  • 4

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)